Neurotrophic factor therapy — Keeping score

1. Gao, W.Q. et al. Neurotrophin-3 reverses cisplatin-induced peripheral sensory neuropathy. Ann. Neurol. 38, 30−37 (1995). | PubMed  | ISI | ChemPort |
2. Emerich, D.F. et al. Protective effect of encapsulated cells producing neurotrophic factor CNTF in monkey model of Huntington's disease. Nature 386, 395−399 (1997). | Article | PubMed  | ISI | ChemPort |
3. Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493−506 (1996). | Article | PubMed  | ISI | ChemPort |
4. Goldberg, Y.P. et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nature Genet. 13, 442−449 (1996). | Article | PubMed  | ISI | ChemPort |
5. Kuida, K. et al. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 384, 368−372 (1996). | Article | PubMed  | ISI | ChemPort |
6. Burke, J.R. et al. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nature Med. 2, 347−350 (1996). | Article | PubMed  | ISI | ChemPort |
7. Koroshetz, W.J., Jenkins, B.G., Rosen, B.R. & Beal, M.F. Energy metabolism defects in Huntington's disease and effects of coenzyme Q₁₀. Ann. Neurol. 41, 160−165 (1997). | PubMed  | ISI | ChemPort |
8. Winkler, J. et al. Reversible Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites after intraventricular administration of nerve growth factor. Ann. Neurol. 41, 82−93 (1997). | PubMed  | ISI | ChemPort |
9. Gash, D.M. et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380, 252−256 (1996). | Article | PubMed  | ISI | ChemPort |

	Top

	Top